COMMUNITY HEALTH CHOICE

February 11, 2025

TIRZEPATIDE (ZEPBOUND) CLINICAL PRIOR AUTHORIZATION CRITERIA PROPOSALS DUE FEB. 14, 2025

BACKGROUND

The Vendor Drug Program (VDP) solicits MCOs for prospective clinical prior authorization criteria proposals before each Drug Utilization Review (DUR) Board meeting. In preparation for the April DUR board meeting, VDP is developing a clinical prior authorization criteria proposal for tirzepatide (Zepbound) to treat moderate to severe obstructive sleep apnea (OSA) in adults with obesity.

KEY DETAILS

VDP is developing a clinical prior authorization criteria proposal for Zepbound as a mandatory clinical prior authorization for the entire Medicaid population. VDP will present Zepbound clinical prior authorization proposal at the April 25, 2025 DUR Board, followed by implementation on May 2, 2025.

ACTION

MCOs must implement the approved prior authorization on May 2, 2025.

MCOs may submit proposals for Zepbound clinical prior authorization by the close of business on Feb. 14.

- Submit proposals based on the required format defined in UMCM 3.29 (MMC/CHIP MCO Pharmacy Website Required Critical Elements). Submitting proposals in this format assists VDP in performing a more comprehensive review and more quickly evaluating proposals. HHSC will return proposals not presented in the required format with a request to re-submit correctly.

- MCOs missing the deadline will have another opportunity to review and provide feedback on the combined prospective Zepbound clinical prior authorization proposal before the next DUR Board meeting.